Stock GBIO GENERATION BIO CO.
Add to a list
To use this feature you must be a member
Log inSign up

Company Generation Bio Co.

Equities

GBIO

US37148K1007

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:30:00 03/05/2024 BST 		5-day change 1st Jan Change
3.17 USD +1.93% Intraday chart for Generation Bio Co. +9.31% +92.12%
04-12 Transcript : Generation Bio Co. - Special Call
03-07 Needham Cuts Price Target on Generation Bio to $10 From $14, Maintains Buy Rating MT

Business Summary

Generation Bio Co. is a biotechnology company. The Company is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The Company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The Company is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases.

Number of employees: 174

Sales per Business

USD in Million2022Weight2023Weight Delta
Genetic Medicines
100.0 %
0 nan % 6 100.0 % -

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 nan % 6 100.0 % -

Managers

Managers TitleAgeSince
Cameron McDonough CEO
 Chief Executive Officer 53 30/09/17
Matthew Norkunas DFI
 Director of Finance/CFO 46 21/07/20
Antoinette Paone COO
 Chief Operating Officer 46 30/09/18
Matthew Stanton CTO
 Chief Tech/Sci/R&D Officer 51 30/09/17
Maren Killackey IRC
 Investor Relations Contact - -
Yalonda Howze LAW
 General Counsel 52 04/04/23
Phillip Samayoa PRN
 Corporate Officer/Principal 37 30/11/18

Members of the board

Members of the board TitleAgeSince
Jeff Jonas BRD
 Director/Board Member 71 30/04/18
Gustav Christensen BRD
 Director/Board Member 76 30/11/17
Jason Rhodes FOU
 Founder 54 31/12/15
Charles Rowland BRD
 Director/Board Member 65 30/07/18
Cameron McDonough CEO
 Chief Executive Officer 53 30/09/17
Anthony Quinn BRD
 Director/Board Member 62 30/11/17
Donald Nicholson BRD
 Director/Board Member 67 30/11/17
Ronald Cooper BRD
 Director/Board Member 61 28/02/21
Catherine Stehman-Breen BRD
 Director/Board Member 61 30/11/17
Dannielle Appelhans BRD
 Director/Board Member 41 14/07/22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 66,489,181 56,857,102 ( 85.51 %) 0 85.51 %

Shareholders

NameEquities%Valuation
Atlas Venture Life Science Advisors LLC
12.45 %
8,279,484 12.45 % 34 M $
T. Rowe Price International Ltd.
10.42 %
6,926,174 10.42 % 28 M $
MODERNA, INC.
8.814 %
5,859,375 8.814 % 24 M $
Fidelity Management & Research Co. LLC
8.051 %
5,352,399 8.051 % 22 M $
Bellevue Asset Management AG
5.441 %
3,617,080 5.441 % 15 M $
BlackRock Advisors LLC
4.558 %
3,029,763 4.558 % 12 M $
Artal Group SA
4.233 %
2,814,191 4.233 % 11 M $
Vanguard Fiduciary Trust Co.
3.839 %
2,552,251 3.839 % 10 M $
Bank of America, NA (Charlotte, North Carolina)
3.803 %
2,527,862 3.803 % 10 M $
EcoR1 Capital, LLC
3.079 %
2,046,867 3.079 % 8 M $

Company contact information

Generation Bio Co.

301 Binney Street

02142, Cambridge

+

http://www.generationbio.com
address Generation Bio Co.(GBIO)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Generation Bio Co.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
3.17 USD
Average target price
7.5 USD
Spread / Average Target
+136.59%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
GENERATION BIO CO. Stock Generation Bio Co.
+92.12% 211M
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 105B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 104B
ARGENX SE Stock argenx SE
+4.40% 22.94B
BIONTECH SE Stock BioNTech SE
-12.15% 22.34B
GENMAB A/S Stock Genmab A/S
-4.36% 19.25B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.79% 14.16B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.63B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. GBIO Stock
  4. Company Generation Bio Co.